Neoadjuvant followed by adjuvant pembrolizumab is recommended to be available as a routine commissioning treatment option for stage III macroscopic resectable melanoma within the criteria set out in this document.

The policy is restricted to 12 years and older only as there is insufficient evidence to confirm safety in patients under the age of 12 years of age.